Amoy Diagnostics Co., Ltd. (300685.SZ)
CNY 20.92
(0.1%)
CNY 20.92
(0.1%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 352.59 Million CNY | 32.57% |
| 2022 | 350.61 Million CNY | -17.12% |
| 2021 | 291.26 Million CNY | 25.47% |
| 2020 | 228.89 Million CNY | 25.59% |
| 2019 | 193.34 Million CNY | 13.99% |
| 2018 | 162.69 Million CNY | 32.44% |
| 2017 | 124.95 Million CNY | 37.99% |
| 2016 | 90.34 Million CNY | 129.43% |
| 2015 | 41.15 Million CNY | 28.93% |
| 2014 | 30.7 Million CNY | 33.33% |
| 2013 | 22.19 Million CNY | 205.77% |
| 2012 | 7.24 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 93.08 Million CNY | -7.37% |
| 2024 Q1 | 70.42 Million CNY | -21.28% |
| 2024 Q2 | 87.85 Million CNY | 11.47% |
| 2023 Q2 | 77.64 Million CNY | 15.48% |
| 2023 Q4 | 114.51 Million CNY | 122.2% |
| 2023 FY | - CNY | 32.57% |
| 2023 Q1 | 67.23 Million CNY | 170.75% |
| 2023 Q3 | 51.53 Million CNY | -33.63% |
| 2022 Q3 | 63.33 Million CNY | 32.08% |
| 2022 Q2 | 47.95 Million CNY | -18.37% |
| 2022 FY | - CNY | -17.12% |
| 2022 Q1 | 58.73 Million CNY | 3.68% |
| 2022 Q4 | 24.83 Million CNY | -60.79% |
| 2021 Q1 | 53.78 Million CNY | -17.16% |
| 2021 FY | - CNY | 25.47% |
| 2021 Q4 | 56.65 Million CNY | -26.07% |
| 2021 Q2 | 72.2 Million CNY | 34.25% |
| 2021 Q3 | 76.63 Million CNY | 6.14% |
| 2020 Q2 | 65.95 Million CNY | 139.05% |
| 2020 FY | - CNY | 25.59% |
| 2020 Q1 | 27.59 Million CNY | -19.28% |
| 2020 Q4 | 64.92 Million CNY | 24.98% |
| 2020 Q3 | 51.94 Million CNY | -21.24% |
| 2019 Q4 | 34.18 Million CNY | -11.31% |
| 2019 FY | - CNY | 13.99% |
| 2019 Q3 | 38.53 Million CNY | -25.27% |
| 2019 Q2 | 51.56 Million CNY | 35.39% |
| 2019 Q1 | 38.08 Million CNY | 8.97% |
| 2018 Q1 | 31.64 Million CNY | 15.62% |
| 2018 Q4 | 34.95 Million CNY | 15.55% |
| 2018 FY | - CNY | 32.44% |
| 2018 Q3 | 30.25 Million CNY | -38.82% |
| 2018 Q2 | 49.44 Million CNY | 56.24% |
| 2017 FY | - CNY | 37.99% |
| 2017 Q1 | 20.3 Million CNY | -39.73% |
| 2017 Q3 | 29.24 Million CNY | -5.85% |
| 2017 Q2 | 31.06 Million CNY | 52.95% |
| 2017 Q4 | 27.37 Million CNY | -6.41% |
| 2016 Q3 | 12.56 Million CNY | -27.59% |
| 2016 Q1 | 17.35 Million CNY | 0.0% |
| 2016 FY | - CNY | 129.43% |
| 2016 Q4 | 33.69 Million CNY | 168.12% |
| 2016 Q2 | 17.35 Million CNY | -0.0% |
| 2015 Q1 | 9.18 Million CNY | 0.0% |
| 2015 FY | - CNY | 28.93% |
| 2015 Q2 | 9.18 Million CNY | 0.0% |
| 2014 FY | - CNY | 33.33% |
| 2013 FY | - CNY | 205.77% |
| 2012 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.86 Billion CNY | 81.046% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.84 Billion CNY | 87.613% |
| Dirui Industrial Co.,Ltd. | 288.83 Million CNY | -22.074% |
| Beijing Strong Biotechnologies, Inc. | 697.99 Million CNY | 49.484% |
| Medicalsystem Biotechnology Co., Ltd. | 475.01 Million CNY | 25.771% |
| Maccura Biotechnology Co.Ltd | 651.98 Million CNY | 45.919% |
| Guangzhou Wondfo Biotech Co.,Ltd | 859.12 Million CNY | 58.959% |
| Guangdong Hybribio Biotech Co.,Ltd. | 236.08 Million CNY | -49.354% |
| BGI Genomics Co., Ltd. | 714.86 Million CNY | 50.676% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -59 Million CNY | 697.53% |